Bronchogen
Bronchogen (Ala-Glu-Asp-Leu, AEDL)
Also known as: AEDL
A Khavinson tetrapeptide sold for lung and bronchial health; in-vitro work only, from one group, with no human trials or pharmacokinetics.
Overview
Bronchogen is proposed to bind DNA and modulate lung-specific genes such as NKX2-1 and the club-cell protein SCGB1A1. Evidence is limited to cell studies from the originating institute. It is sold as a Russian supplement and by Western research vendors, usually as sublingual capsules, with no data that it is absorbed.
Mechanism of action
Proposed DNA-binding modulation of bronchial epithelial gene expression.
Key studies & citations
- In vitro2016
Short peptides and telomere length regulator hormone irisin
Khavinson-group cell study on short peptides; no lung-specific human data.
Bulletin of Experimental Biology and Medicine
Frequently asked questions
Does Bronchogen help lungs?
There is no human study. The only data are cell experiments from one lab.